He use ethylmethylhydroxypyridine succinate in the treatment of patients with heart failure
Sidorenko, G.I.; Komissarova, S.M.; Zolotukhina, S.F.; Petrovskaia, M.E.
Kardiologiia 51(6): 44-48
2011
ISSN/ISBN: 0022-9040 PMID: 21878070 Document Number: 651179
We studied impact of ethylmethylhydroxypyridine succinate n the course of chronic heart failure during 3 years follow-up after myocardial infarction. Dynamics of objective and subjective parameters was assessed in 100 patients; 48 patients received conventional therapy (control group) and 52 patients received conventional therapy plus ethylmethylhydroxypyridine succinate (main group). Addition of ethylmethylhydroxypyridine succinate resulted in decreases of rates of complications, mortality, and re-hospitalizations. Increases of myocardial contractile function, myocardial adaptation, as well as improvement of range of biochemical parameters were also observed. The latter changes were indicative of antioxidant, anti-inflammatory, anti-stress activities of Ethylmethylhydroxypyridine succinate. Moreover, antidepressant and antineurotic effects of complex therapy including ethylmethylhydroxypyridine succinate was confirmed.